Neoadjuvant treatment with trastuzumab and pertuzumab plus fulvestrant in older patients with HER2-positive, ER-positive early breast cancer.

被引：0
|
作者：
Celis, Juan Jose [1 ]
Rodriguez, Vanessa [1 ]
Rodriguez, Crismar [1 ]
机构：
[1] Soc Anticancerosa Venezuela, Caracas, Venezuela
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 23_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.23_suppl.13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [31] Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
    Wang, B.
    You, S.
    Xie, Y.
    Xu, F.
    Sang, D.
    Luo, T.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S362
  • [32] Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: outcomes in Chinese patients in the APHINITY study
    Shao, Zhimin
    Tseng, Ling-Ming
    Huang, Chiun-Sheng
    Pang, Da
    Yang, Youngsen
    Li, Wei
    Liao, Ning
    Geng, Cuizhi
    Zhang, Qingyuan
    Xu, Binghe
    Liu, Donggeng
    Kwong, Ava
    Yu, Mandy
    Sun, Guofang
    Mobus, Volker
    Dent, Susan
    Arahmani, Amal
    Borthwick, Gillian
    Henot, Frederic
    von Minckwitz, Gunter
    Jiang, Zefei
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) : 345 - 353
  • [33] Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
    Liu, Yan-cui
    Ma, Ying
    An, Ning
    Sun, Ping
    Wang, Ying
    Sun, Cheng
    MEDICINE, 2019, 98 (38)
  • [34] Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
    Harbeck, Nadia
    BREAST, 2022, 62 : S12 - S16
  • [35] A Multicentre Study of Pathological Complete Response in HER2-positive Early Breast Cancer Treated with Neoadjuvant Pertuzumab and Trastuzumab
    Chambers, J.
    Maxwell, A.
    Kingdon, S.
    CLINICAL ONCOLOGY, 2019, 31 (07) : E106 - E106
  • [36] Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Nakatsukasa, Katsuhiko
    Taguchi, Tetsuya
    Sugimoto, Riho
    Sakaguchi, Kouichi
    Kotani, Tatsuya
    Hukuda, Kenichirou
    Kawakami, Sadao
    Hujiwara, Ikuya
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer
    M. Tanioka
    K. Sakai
    T. Sudo
    T. Sakuma
    K. Kajimoto
    K. Hirokaga
    S. Takao
    S. Negoro
    H. Minami
    K. Nakagawa
    K. Nishio
    Breast Cancer Research and Treatment, 2014, 147 : 513 - 525
  • [38] Real-world evidence regarding the efficacy and toxicity of neoadjuvant trastuzumab and pertuzumab in the management of HER2-positive early-breast cancer.
    Hall, Benjamin James
    Bhojwani, Ajay Ashok
    Innes, Helen
    Ahmed, Eliyaz
    Cliff, Joanne
    Malik, Zaf
    O'Hagan, Julie Elizabeth
    Tolan, Shaun
    Hall, Allison
    Hayat, Khizar
    Errington, Douglas
    Alam, Farida
    Thorp, Nicky
    Flint, Helen
    Law, Andrea
    Wong, Helen
    O'Reilly, Susan
    Jackson, Richard
    Cicconi, Silvia
    Palmieri, Carlo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer
    Tanioka, M.
    Sakai, K.
    Sudo, T.
    Sakuma, T.
    Kajimoto, K.
    Hirokaga, K.
    Takao, S.
    Negoro, S.
    Minami, H.
    Nakagawa, K.
    Nishio, K.
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 147 (03) : 513 - 525
  • [40] Pertuzumab in HER2-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
12345